Retatrutide TRIUMPH-1: the phase 3 results

What TRIUMPH-1 found, in one paragraph

TRIUMPH-1 randomized 2,339 adults with obesity or overweight without diabetes to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. Mean weight loss was 19.0%, 25.9%, and 28.3% across the three doses, versus 2.2% on placebo. At the 12 mg dose, 45.3% of participants lost 30% or more of their body weight. The data are topline results announced by Eli Lilly on May 21, 2026.

Retatrutide is the most-watched obesity compound in late-stage development, and on may 21, 2026 Eli Lilly released the first pivotal phase 3 readout for it. the headline number -- up to 28.3% mean weight loss -- is real and it is large. it is also a topline company announcement rather than a peer-reviewed paper, and there is important context between the press release and what the data actually mean for a real person. this post walks the numbers, the dose-by-dose detail, the side-effect profile, and the regulatory reality.

The short version: retatrutide produced the highest mean weight loss reported in any phase 3 obesity program to date, the safety signals look like a steeper version of the familiar GLP-1 class profile, and the drug is still investigational. none of that changes the fact that nobody can legally prescribe it yet.

The dose-by-dose weight loss numbers

At 80 weeks, retatrutide produced mean weight reductions of 19.0% (47.2 lb) at 4 mg, 25.9% (64.4 lb) at 9 mg, and 28.3% (70.3 lb) at 12 mg, against 2.2% for placebo. A subgroup with baseline BMI of 35 or higher who continued in an extension reached a mean of 30.3% (85.0 lb) at 104 weeks. The dose-response relationship was clear and steep.

TRIUMPH-1 (trial identifier NCT05929066) enrolled 2,339 participants in a 1:1:1:1 split across three retatrutide doses and placebo. dosing started at 2 mg once weekly and escalated every four weeks to the assigned target. the primary analysis ran to 80 weeks. a subset of participants with a baseline body mass index of 35 or higher continued into an extension to 104 weeks.

Two secondary thresholds are worth pulling out. at the 12 mg dose, 45.3% of participants lost 30% or more of their body weight, a magnitude historically associated with bariatric surgery rather than medication. and 65.3% of the 12 mg group reached a body mass index below 30, meaning they were no longer in the obesity category by the end of the trial. the extension data are notable too: the higher-BMI group at 12 mg was still losing weight past 80 weeks and reached a mean of 30.3% (about 85.0 lb) at 104 weeks, suggesting the curve had not fully flattened for everyone at the standard endpoint.

For scale, this is the comparison the field has been waiting on. the GLP-1 comparison tool puts retatrutide next to semaglutide and tirzepatide; semaglutide produced roughly 15% in the STEP program and tirzepatide up to 22.5% in SURMOUNT-1. a triple agonist landing near 28% at the top dose is a real step up in headline efficacy, with the caveats below.

The cardiometabolic and secondary results

Beyond weight, the 12 mg group showed a mean waist circumference reduction of about 24.1 cm (9.5 inches) plus improvements in non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein. Eli Lilly reported these as secondary endpoints. Detailed glycemic and full cardiometabolic data are expected with the complete trial presentation rather than the topline release.

Weight is the headline, but obesity trials increasingly report the downstream metabolic markers, and TRIUMPH-1 followed that pattern. the company described improvements from baseline in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein. the waist reduction in the 12 mg arm, reported as roughly 24.1 cm, is consistent with the large total-weight numbers.

A few caveats apply. the glucagon receptor component of retatrutide is the part that most differentiates it from tirzepatide, and glucagon agonism can raise hepatic glucose output and heart rate, so the full glycemic profile and any cardiovascular signal matter a great deal. those details are exactly the kind of thing a topline press release does not fully quantify. the dedicated TRIUMPH-2 trial in type 2 diabetes and TRIUMPH-3 in established cardiovascular disease are designed to answer those questions, and they had not read out at the time of this writing.

The side-effect profile

Adverse events were gastrointestinal and dose-related. At 12 mg, approximate rates were 42.4% nausea, 32.0% diarrhea, 26.1% constipation, and 25.3% vomiting, mostly mild to moderate. Dysesthesia (skin tingling) occurred in roughly 5% to 12.5% of retatrutide users. Discontinuation due to adverse events rose with dose to 11.3% at 12 mg, versus 4.9% on placebo.

The tolerability story is the familiar incretin pattern, scaled up. nausea, diarrhea, constipation, and vomiting were the dominant adverse events, they were dose-related, and most cases were mild to moderate. at the top 12 mg dose the reported rates were about 42.4% nausea, 32.0% diarrhea, 26.1% constipation, and 25.3% vomiting, against single-digit-to-low-teens rates on placebo.

One effect that stands out from the dual-agonist class is dysesthesia, an altered or tingling skin sensation, reported in roughly 5% to 12.5% of retatrutide participants compared with under 1% on placebo. it was generally described as mild. the practical readout from the safety data is the discontinuation rate: about 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg stopped because of adverse events, versus 4.9% on placebo. that gradient is the tradeoff in plain terms -- the dose that produces the most weight loss is also the dose more people cannot stay on.

Why retatrutide is still investigational

Retatrutide is not FDA-approved and cannot be legally prescribed. The TRIUMPH-1 figures came from a company press release, not a peer-reviewed publication, and the broader TRIUMPH program (diabetes and cardiovascular trials) had not fully read out. Eli Lilly indicated a regulatory submission is anticipated in 2026, but any approval would follow regulatory review of the complete data.

This is the part the excitement tends to skip. as of may 2026, retatrutide is an investigational molecule. no regulator has approved it for any indication, no clinician can prescribe it, and there is no quality-assured product on the market. material sold online as research retatrutide sits entirely outside regulatory oversight, which means identity, purity, and actual dose cannot be verified, and using it carries risks that the controlled trial population did not face.

There is also a difference between a topline announcement and the evidence base. the numbers in this post come from Eli Lilly's may 21, 2026 press release. they are almost certainly directionally accurate, but the peer-reviewed paper -- with full statistics, prespecified analyses, subgroup breakdowns, and independent review -- is the document that the field ultimately judges a drug on. detailed TRIUMPH-1 results were slated for a scientific congress, and the company indicated a regulatory submission is anticipated in 2026. approval, if it comes, follows regulatory review of the entire TRIUMPH program, not a single trial. for context on how the FDA handles approval timelines for this drug class, see the FDA peptide reclassification guide and the overview of FDA-approved peptides to understand which compounds in this space have already cleared regulatory review.

If you want the mechanism behind the numbers -- how simultaneous GIP, GLP-1, and glucagon receptor activation produces this profile, and why the glucagon arm is the variable to watch -- our retatrutide course walks through the receptor pharmacology and the clinical evidence in structured units. for how this slots in against the approved options and the off-ramp question that applies to every drug in this class, the tirzepatide muscle, plateau, and off-ramp guide covers the principles that transfer across compounds.

How to read trial headlines like this one

Mean trial figures hide the spread: some participants far exceed the average and some respond little or stop early. Headline percentages also come from the highest-dose arm under structured lifestyle support, on a selected trial population. Topline press releases precede peer review. Treat 28.3% as the top of a distribution under ideal conditions, not a number any individual should expect.

A 28.3% mean is the average of a wide distribution. in any obesity trial, some participants lose far more than the mean, some lose much less, and some discontinue because of side effects and are handled by the statistical analysis rather than walking out with that result. the headline is also the top-dose arm, which carries the highest adverse-event burden, and trial participants receive structured diet and lifestyle support that real-world users may not. the CagriSema REDEFINE-1 trial analysis illustrates the same issue in a different compound -- large headline numbers that require careful reading of the full trial design.

None of that diminishes the result. it contextualizes it. the honest summary is that retatrutide, in its first pivotal phase 3 trial, produced the largest mean weight loss the obesity field has reported, with a dose-related side-effect profile in the expected class and a discontinuation gradient that scales with dose, and it remains an investigational compound that nobody can yet legally prescribe. that is the research, and the research is genuinely impressive on its own without the hype.